Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.

Slides:



Advertisements
Similar presentations
Safety Reporting IN Clinical Trials
Advertisements

Integration of Viral Hepatitis Prevention with STD Prevention: What Health Professionals Should Know Presenter: Jay Todd, Training and Public Education.
U.S. Food and Drug Administration Notice: Archived Document. The content in this document is provided on the FDA’s website for reference purposes only.
Designing Clinical Research Studies An overview S.F. O’Brien.
Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.
Assessing the knowledge, attitudes and experiences of Myanmar youth in regards to HIV/AIDS Natalia Talikowski.
Asking Patients About Sexual Health and Behavior for Improved Quality in Prevention and Care
Unit 1 Part 1 Blood Collection
Adapting AABB Donor Regulation at KCBB. Why? Blood safety starts by bleeding safe Blood donors “Safe Blood starts with me” BTS need to Implement adequate.
Public Workshop: Quarantine Release Errors in Blood Establishments September 13, 2011 QREs Past, Present and Future Sheryl A. Kochman Deputy Director Division.
Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Department of Health and Human Services Measuring Clinical Lab Ordering Quality: Theory and Practice Steven M. Asch MD MPH VA, RAND, UCLA April 29, 2005.
Health Line of Business Revised Health Domains January 26, 2005 Outcomes / Domains have been revised.
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
INSTITUTIONAL PHARMACY PRACTICE STANDARDS
Current standards, donor safety, and blood supply
Prelim 11/14/11. 2 nd Semester, 3 rd Year Level  The Early 1900’s, With The Work Of An Industrial Engineer Named Frederick Winslow Taylor.  “Father.
Dengue Virus and Its Risk to the U.S. Blood Supply
Manish Chaudhary BPH, MPH
RENI PRIMA GUSTY, SK.p,M.Kes
CBER 1 Current standards, donor safety and blood supply Orieji Illoh, MD Office of Blood Research and Review Center for Biologics Evaluation and Research.
Role of Clinicians in Promoting Voluntary Blood Donation Dr. Anju Verma.
Clinical Pharmacy Basma Y. Kentab MSc..
Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.
Donor Selection Criteria Dr. Mindy Goldman Transfusion Medicine Residents May 24, 2011.
CBER Hemoglobin/Hematocrit Acceptance Standards and Interdonation Interval in Blood Donors Summary and Questions for the Committee Blood Products Advisory.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
Deferral of MSM by Andrew I. Dayton, M.D., Ph. D. The HIV epidemic in the U.S.A. is generally recognized to have started just after Currently MSM.
21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
+ Dr. Megan Rowley Consultant in Transfusion Medicine Blood Transfusion.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
And the order changeth …. Evolving protocols for TTI testing
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
Medical Audit.
Self-reported cognitive and emotional effects and lifestyle changes shortly after preventive cardiovascular consultations in general practice Dea Kehler.
Safe Immunization Practices and Prevention of Hepatitis B and C Susan Mackay Behaviour Change Project Safe Injection Global Network.
From the Lab to Market Unit 3.04 Understanding Biotechnology research & Development.
Monthly Journal article review: Vimmi Kang PGY 2
CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.
Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.
Blood Center Experience with Double Red Cell Collections by Apheresis: Adverse Events and Impact on Capacity Brian Custer, Hany Kamel, Marj Bravo Peter.
FDA EID Workshop: Day 2 Organs, Tissues and Cells Melissa A. Greenwald, MD Blood Products Advisory Committee 26 July 2010 Gaithersburg, MD.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Dispensary and Administration Site Information Presentation.
Introduction.
Modeling Risk of vCJD in US Donors – Residual Risk and Efficiency of Donor Deferral Alan E. Williams, Ph.D. Director, Division of Blood Applications Office.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
Identification and Deferral of Tissue Donors for Possible BSE/vCJ-D Exposure: Estimating the Impact Alan E. Williams, Ph.D. Director, Division of Blood.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications.
WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary of November 2010 ACBSA for FDA’s BPAC December 2010 CDR Richard Henry, USPHS.
Transfusion Related Acute Lung Injury (TRALI)
 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.
Bad Blood? An Investigation of the MSM Ban on Blood Donation Lauren Lacy Abstract In 1983, the Food and Drug Administration (FDA), responding to the AIDS.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
A new evaluation of the risk of transfusion-transmitted HIV prevented by a 12-month deferral before donation for men who have sex with men Josiane Pillonel,
Primary Investigator: Prof. P Reddy Project Director: Ms S James
Controlling Measuring Quality of Patient Care
Air Carrier Continuing Analysis and Surveillance System (CASS)
Nursing Process in Pharmacology
Joint (PT CBS BLC and NAC) Meeting
Dr. Nishi Jaswal Assistant Professor
SELECTING RESEARCH DESIGN
Lecture 4 Study design and bias in screening and diagnostic tests
Presentation transcript:

Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008

2 Plan  Importance of donor criteria  Current donor screening and deferrals  Factors affecting donor responses  Evolution of donor criteria  Assessment of questionnaire, criteria

3 RECIPIENT SAFETY DONOR CRITERIA BLOOD AVAILABILITY DONOR SATISFACTION DONOR SAFETY OPERATIONAL EFFICIENCY PUBLIC PERCEPTION

4 Donor screening  Donor vital signs  Donor hemoglobin (Hgb)  Donor assessment questionnaire (DAQ) – Questions 1-13 self-administered – Questions administered by staff – 87 items queried – Identical for 1 st time, repeat donors

5 Donor deferrals ~ 15% of donors deferred on clinic

6 Indefinite deferrals 4% of deferrals are indefinite

7 Indefinite deferral, HIV or hepatitis risk First time donors,

8 Prevalence of HCV per 100,000 donations

9 Factors affecting donor responses  Donor characteristics – Language comprehension – Memory – Motivation

10 Factors affecting donor responses  Mode of administration – Self-administration – Face-to-face interview – Computer administered – Privacy  Formulation and order of questions

11 Components of response  Comprehension  Retrieval  Judgement  Selecting and reporting answers

12 Evolution of donor criteria  Developed over time as new knowledge, threats emerged  Many FDA, Health Canada requirements  Little validation that question formulation elicits appropriate information  Differences across jurisdictions demonstrates not based on scientific data

13 Donor selection vs testing 100%  10% 0123    Laboratory Test Utility of donor selection

14 Methods of assessment of criteria  Impossible to do a randomized, controlled trial  Difficult to isolate the effect of an individual criteria  Difficult to choose appropriate outcome measure  Difficult to prove that there will be “zero risk increase” for recipients or donors with a given change in criteria

15 Methods of assessment, donor questionnaire  Surveys of undeclared, reportable risks  Operational outcome measures – Post-donation information  Cognitive research methods – Degree of correlation, alternative wording – Qualitative methods such as focus groups

16 Methods of assessment, donor questionnaire  Evaluation of donor recall of items queried  DAQ in various formulations and modes of administration – Self-administered – Audiovisual computer-assisted format

17 Assessment of changes, recipient safety  Rates of transmission of HIV, hepatitis are too low to measure changes, risk modelling can be done  Perform TD testing in deferred donors  Assess risk factors, TD positive donors  Perform donor surveys to estimate anticipated donor loss/gain  Follow TD marker rates after making a change  Experience in other countries

18 Recipient safety criteria  Some successful changes – Removal of the question about fever and headache in the week before donation for WNV – Shortening of deferral period from 12 to 6 months for tattoo, piercing, needle-stick injury

19 Recipient safety criteria  Some challenges – Question and deferral for having sex with someone whose sexual background you don’t know – Intranasal cocaine use – Indefinite deferral for men who have sex with men, even once since 1977

20 History of deferral criteria, MSM  Implemented in Canada in the mid-1980s  By 1989, listed on the donor health assessment questionnaire  Requirement by FDA, Health Canada, Canadian Standards for Blood and Blood Components  FDA Blood Products Advisory Committee held workshops in 2000 & 2005 to reassess criteria

21 History of deferral criteria, MSM  Although FDA has not changed their requirement, AABB and US blood suppliers (ABC, ARC) have supported a change to a 12 month deferral period  Neither AABB, ABC, or ARC has supported removal or modification of the deferral criteria other than a change to a shorter deferral period

22 History of deferral criteria, MSM  In Canada, 2001 joint CBS/Héma-Québec Consensus Conference on Optimizing the Donor Process – Current process extremely safe – No specific recommendations for changes for the MSM criteria – Advocated continued reassessment of the value of screening questions, based on evolving data

23 Challenges in maintaining the current criteria  Time period “since 1977” is effectively becoming a life-time deferral  Advances have been made in the 2 other components of blood safety; testing and Good Manufacturing Practices  Direct donor loss of individuals deferred by the criteria  Indirect donor loss of individuals not directly affected, but feel criteria is discriminatory

24 Challenges in maintaining the current criteria  Perceived misalignment with deferral periods for other risk categories  Potential view of Canadian Blood Services as unnecessarily discriminatory by the public  Changes in social policy have occurred with respect to a group that has been discriminated against in the past

25 Challenges in changing the current criteria  Lack of data to support possible approaches  Regulated system with very low measurable risks, Mathematical modelling based on many assumptions  Extremely difficult to perform studies to obtain data

26 Challenges in changing the current criteria  Any incremental risk is borne by recipients, who have a right to the safest possible transfusion  Public history of past tragedies of HIV, HCV transmission

27 Assessment of changes, donor safety  Analysis of adverse events, current criteria  Adverse effects in autologous donors  Experience in other countries  Increase surveillance after changing criteria

28 Donor safety criteria  Some successes – Acceptance of donors on antihypertensive medications – Acceptance of donors with celiac disease – Increase in maximal age of donation for regular donors

29 Donor safety criteria  Some challenges – Hemoglobin deferral criteria for female donors – Donors pulse rate and regularity – Donors on insulin

30 Conclusions  Donor criteria play an important part in ensuring donor and recipient safety, adequacy of supply  Approximately 15% of donors are deferred on the clinic, 4% of donors are deferred indefinitely  Many factors affect donor responses to screening questions  Evaluation of the donor questionnaire, and criteria to protect recipients or donors is challenging